Lilly’s Lobby Spend — Vs. Amgen’s: Both Well Below… Each Of Merck And Pfizer.

Here is the Lilly spend details, for Q2 2023. . . pretty unremarkable, overall.

We will cover Amgen’s — tomorrow, but this is the Indy firm:

…Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil….

Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the “Inflation Reduction Act” (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act….

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the “Inflation Reduction Act” (HR.5376); CMS National Coverage Determination on Alzheimer’s disease; The INSULIN Act….

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access….

Pharmaceutical intellectual property issues….

Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax….

Hospital discounts; 340B program….

Now you know. With last quarter’s Lilly spend, immediately above. Smile….

नमस्ते